Videos

Marcia Brose, MD and Lori Wirth, MD, discuss molecular testing considerations in patients with radioiodine-refractory DTC.

Experts in the management of thyroid cancer discuss radioactive iodine therapy and the clinical implications of mutational status in RAI- refractory DTC.

The panel of experts share their insights into the definition and clinical presentation of radioiodine-refractory DTC.

Andrew Gianoukakis, MD, reviews the treatment and management options for a 71-year-old woman with RAI- refractory differentiated thyroid cancer.

Experts in thyroid cancer discuss treatment considerations surrounding the use of radioiodine therapy in patients with thyroid cancer.

Andrew Gianoukakis, MD, reviews the case of a 71-year-old woman with RAI-refractory differentiated thyroid cancer and the panel discuss relevant clinical trial data.

In this second video of the series, Phillip J. Koo, MD, of the Banner MD Anderson Cancer Center explains the role of nuclear imaging (PET) and PSMA in the diagnosis and treatment of prostate cancer.

Ingrid Glimelius, MD, PhD, a senior lecturer and assistant professor in the Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala Universitet, discusses the lasting effects of lymphoma treatments.

Jorge E. Cortes, MD, discusses the current therapies available to treat patients with chronic myeloid leukemia and how to choose between them when there is similar efficacy.

Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.

An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.

Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.

A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.

Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.

Robert Coleman, MD, FACOG, FACS, discussed how immunotherapy in lung cancer has been widely accepted and adopted in the community oncology setting.

Tanios Bekaii-Saab, MD, FACP, concludes with a discussion of potential outcomes for a 65-year-old patient with stage 4 metastatic colorectal cancer.

Dr Bekaii-Saab reviews options for subsequent lines of therapy for metastatic colorectal cancer, including non-chemotherapy options.

An expert elaborates on the importance of the capecitabine + bevacizumab combination therapy for metastatic colorectal cancer, as well as what signs of progression or recurrence to look for in patients.

Dr Bekaii-Saab discusses therapy options for first-line treatment of metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, FACP, provides an overview of a case involving a 65-year-old man diagnosed with stage 4 metastatic colorectal cancer.

Lori Wirth, MD, discusses the relevance of patient-reported outcomes from the phase 1/2 LIBRETTO-001 study in of selpercatinib in patients with RET-altered medullary thyroid cancer or advanced thyroid cancer.

An expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.

Lyndsay Willmott, MD, explains the tolerability of PARP inhibitors for ovarian cancer and how to discuss dose reductions with patients.

A key opinion leader shares data from a phase III, ARIEL3, clinical trial on rucaparib maintenance treatment for ovarian cancer.

Dr. Lyndsay Willmott discusses the front-line therapy options for ovarian cancer and the factors considered in choosing maintenance therapies.

The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.

An oncologist explains the importance of molecular testing in ovarian cancer and the implications of testing on treatment selection.

Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.

Lyndsay Willmott, MD, presents the case of a 57-year-old woman with ovarian cancer.

Neeraj Agarwal, MD, discusses how the prostate-specific antigen responses correlate with survival outcomes in 2 phase 3 trials of apalutamide in patients with advanced prostate cancer.